Frankfurt
Germany
Institut für Klinisch-Onkologische Forschung Krankenhaus Nordwest Frankfurt/Main
Cholangiocarcinoma, chemotherapy, Irinotecan, second line
oesophageal cancer, lymph nodes, prognostic factor, microarchitecture, immune system, survival